Integrative Research Laboratories AB   Report issue

For profit Phase 2
Founded: Gothenburg Sweden (2013)

Organization Overview

First Clinical Trial
2016
NCT03531060
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Integrative Research Laboratories AB | Integrative Research Laboratories AB (IRLAB)

Active Ingredients

Drugs in Phase 2 Trials (2)

mesdopetam (3 trials)

pirepemat (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dyskinesias (Phase 2)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2